XPOVIO, known generically as selinexor, is manufactured, developed, and commercialized by Karyopharm Therapeutics Inc. It is a first-in-class, oral selective inhibitor of nuclear export medicine designed to treat specific hematologic malignancies, including multiple myeloma and diffuse large B-cell lymphoma. The company produces and distributes the pharmaceutical product globally through its specialized commercial infrastructure and international distribution partnerships.